CLAIM CARDS
Claim Cards
Atomic claims extracted from accepted Researka artifacts, with source support, contradiction state, and provenance links when available.
Filtered to publication 1902d5a5-6019-42ed-9023-004a0ae15784
exploratory
What does the current evidence establish about Bempedoic Acid Longevity and human geroscience? This synthesis tests the thesis that evidence for Bempedoic acid is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Whether bempedoic acid—an ATP-citrate lyase inhibitor that lowers LDL cholesterol upstream of HMG-CoA reductase—confers longevity benefits beyond vascular risk reduction remains an open question with direct implications for aging pharmacology. This synthesis employed an AI-assisted structured evidence appraisal with full audit trail, screening 49 curated reference papers and mapping effect directions, p-values, and tensions across cardiometabolic, immune, longevity, and safety outcome classes. Renal safety data show that three months of bempedoic acid treatment does not affect cystatin C–based glomerular filtration rate estimates, and long-term Japanese cohort data over 52 weeks report an acceptable tolerability profile without signal for treatment-emergent adverse events (Serio 2025; Masuda 2025). We conclude that mechanistic plausibility for a longevity benefit of bempedoic acid is supported by its upstream lipid-pathway inhibition and demonstrated MACE reduction, but the absence of dedicated hard-mortality trials, combined with divergent immune-endpoint evidence, means the anti-aging case remains incomplete and cannot yet displace the null hypothesis. Definitive resol
Contradiction: none
Sources: 5
exploratoryThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating.
Contradiction: none
Sources: 5
exploratoryPer-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.
Contradiction: none
Sources: 5
exploratoryEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune, longevity, safety, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.
Contradiction: none
Sources: 5
exploratorySource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.
Contradiction: none
Sources: 5
exploratoryOutcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence.
Contradiction: none
Sources: 5
exploratory| Cardiometabolic | n=19; claims=1675 | null signal in 14/19 sources | 8 indirect; 1 mechanistic; 10 review | limited corpus depth in this outcome class |
Contradiction: none
Sources: 5
exploratory| Contextual Adjacent Evidence | n=17; claims=832 | null signal in 11/17 sources | 9 indirect; 8 review | limited corpus depth in this outcome class |
Contradiction: none
Sources: 5
exploratory| Immune | n=4; claims=496 | null signal in 2/4 sources | 3 indirect; 1 review | limited corpus depth in this outcome class |
Contradiction: none
Sources: 5
exploratory| Frailty | n=1; claims=6 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |
Contradiction: none
Sources: 5
exploratoryThe retained bempedoic acid longevity corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.
Contradiction: none
Sources: 5
exploratoryThe cardiometabolic evidence packet includes 19 source-level summaries and 1675 high-confidence observations. Directional coding within this packet is mixed=1, null=14, positive=1, unclear=3, and directness coding is indirect=8, mechanistic=1, review=10. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.
Contradiction: none
Sources: 5
exploratoryRepresentative sources include Kibret 2025, Filippo 2023, Zheng 2025. This outcome is interpreted within its own packet first; any broader synthesis is deferred until the cross-domain section so that the writer cannot merge evidence from unrelated outcome classes.
Contradiction: none
Sources: 5
exploratoryThe contextual adjacent evidence packet includes 17 source-level summaries and 832 high-confidence observations. Directional coding within this packet is mixed=2, null=11, positive=2, unclear=2, and directness coding is indirect=9, review=8.
Contradiction: none
Sources: 5
exploratoryDirectional coding within this packet is negative=1, null=2, positive=1, and directness coding is indirect=3, review=1.
Contradiction: none
Sources: 5
exploratoryDirectional coding within this packet is negative=1, null=1, unclear=1, and directness coding is review=3.
Contradiction: none
Sources: 5
exploratoryDirectional coding within this packet is null=1, positive=1, and directness coding is review=2.
Contradiction: none
Sources: 5
exploratoryDirectional coding within this packet is null=1, unclear=1, and directness coding is indirect=1, review=1.
Contradiction: none
Sources: 5
exploratoryDescriptive findings remain separate from interpretation and endpoint-specific boundaries. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation
Contradiction: none
Sources: 5
exploratoryImmune is retained as a separate Results slice (n=4; null signal in 2/4 sources; 3 indirect; no direct clinical anchor) and is not pooled into adjacent endpoint classes.
Contradiction: none
Sources: 5
exploratoryLongevity is retained as a separate Results slice (n=3; null signal in 1/3 sources; not classified; no direct clinical anchor) and is not pooled into adjacent endpoint classes.
Contradiction: none
Sources: 5
exploratorySafety and Comorbidity is retained as a separate Results slice (n=2; null signal in 1/2 sources; 1 indirect; no direct clinical anchor) and is not pooled into adjacent endpoint classes.
Contradiction: none
Sources: 5
exploratoryFrailty remains a separate Results slice (n=1; claims=6; null signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.
Contradiction: none
Sources: 5
exploratoryOutcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence.
Contradiction: none
Sources: 5
exploratory| Cardiometabolic | n=19; claims=1675 | null signal in 14/19 sources | 8 indirect; 1 mechanistic; 10 review | limited corpus depth in this outcome class |
Contradiction: none
Sources: 5
exploratory| Contextual Adjacent Evidence | n=17; claims=832 | null signal in 11/17 sources | 9 indirect; 8 review | limited corpus depth in this outcome class |
Contradiction: none
Sources: 5
exploratory| Immune | n=4; claims=496 | null signal in 2/4 sources | 3 indirect; 1 review | limited corpus depth in this outcome class |
Contradiction: none
Sources: 5
exploratory| Frailty | n=1; claims=6 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |
Contradiction: none
Sources: 5
exploratoryThe retained bempedoic acid longevity corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.
Contradiction: none
Sources: 5
exploratoryThe cardiometabolic evidence packet includes 19 source-level summaries and 1675 high-confidence observations. Directional coding within this packet is mixed=1, null=14, positive=1, unclear=3, and directness coding is indirect=8, mechanistic=1, review=10. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.
Contradiction: none
Sources: 5